Asymmetric depth filtration for isolation of EVs or other desired nanoparticles from a biological or other fluid with high yield and purity in a simple, cost-effective manner. Such a method includes passing the biological fluid through the asymmetric depth filter (e.g., in a single pass) where the fluid is introduced into the filter at an entry portion, where components of the biological fluid pass through the wider entry portion of the pores before advancing towards the narrower exit portion of the pores, wherein EVs in the fluid become reversibly entrapped within the wider portion of the pores, while similarly sized soft, low-density lipids and/or proteins are pushed more deeply into the filter, so that the reversibly entrapped EVs can be released by simply reversing the flow, while the similarly sized soft low-density lipids and/or proteins remain permanently entrapped within the pores of the filter.
Disclosed herein are modified phagocytes comprising chimeric antigen receptors (CARs). Also disclosed herein are methods of treating cancer using the modified phagocytes and methods of making the modified phagocytes.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 27/62 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosolsInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electric discharges, e.g. emission of cathode
G01N 27/26 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variablesInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by using electrolysis or electrophoresis
An example method to form a fracture system includes generating a back flow or at least a lower pressure in a first well at a first zone. The back flow includes flowing a material from the first zone towards an outlet of the first zone and the lower pressure includes actively decreasing the pressure in the first zone. It is noted that the back flow may cause the first zone to exhibit the lower pressure (i.e., the back flow causes the first zone to exhibit a lower pressure than if there was no back flow). The method also includes hydraulically stimulating a second well at a second zone. Hydraulically stimulating the second well may form a fracture network between the first zone and the second zone.
In one aspect, disclosed herein are new hybridization probes that contain fluorinated carbon tags (F), methods of making these hybridization probes, and methods for using these hybridization probes for affinity capture of the probes both in purification during production and in the enrichment process using fluorous substrates. In certain embodiments, the hybridization probe comprises a) a polynucleotide having a 3′ end and a 5′ end and comprising about 20 to about 200 nucleotide units and b) one or more fluorinated affinity tags, wherein each affinity tag comprises one or more polyfluorinated carbon chains each comprising 3-30 carbon atoms; wherein the polynucleotide comprises a sequence complementary or substantially complementary to a target sequence within a target nucleic acid.
Processing flows and related systems and methods are disclosed. A computing system includes one or more data interfaces, one or more other components, and a controller. The one or more data interfaces are configured to provide an interface to a data source. The one or more other components include one or more controller plugins, one or more processing nodes, or both the one or more controller plugins and the one or more processing nodes. The controller is configured to manage interactions between the one or more data interfaces and the one or more other components and enable a user to chain together the one or more data interfaces and the one or more other components according to one or more flows. The one or more controller plugins are configured to provide results of the one or more flows to one of a user interface and a system interface.
A method and system that substantially sharpens the depth of focus. The method includes selecting a group of frequencies where the group of frequencies include a plurality of unique frequencies, assigning one of the frequencies in the group of frequencies to two or more of a plurality of transducers, driving the plurality of transducers to generate a plurality of beamlets where each beamlet includes a wave, and emitting the plurality of beamlets toward the target thereby generating an ultrasound field with reduced focal volume. The improvement in the focal volume using this method can comprise a factor of 10 or more, depending on the frequency bandwidth available to the system. The method, which can be applied for diagnostic and therapeutic applications, is entirely non-invasive and does not require labeling or a modification of elements or objects within the target space.
A thermopneumatic interface includes one or more pneumatic inlet ports in fluid communication with one or more pneumatic outlet ports and a cooling loop extending through the thermopneumatic interface. The cooling loop is configured to maintain the thermopneumatic interface at a baseline temperature. The one or more pneumatic outlet ports are configured to contact a surface of a microfluidic chip. Each pneumatic inlet port is configured to receive a change in pressure and provide the change in pressure to a corresponding pneumatic outlet port. The thermopneumatic interface is configured to maintain the microfluidic chip at the baseline temperature.
F28F 3/04 - Elements or assemblies thereof with means for increasing heat-transfer area, e.g. with fins, with recesses, with corrugations the means being integral with the element
Disclosed herein is a robotic ankle foot prosthesis that replicates the key biomechanical functions of the biological ankle and toe joints while matching the weight, size, and battery life of passive microprocessor-controlled prostheses. A single actuator powers the ankle and toe joints. The mechanism maximizes the mechanical energy regeneration during walking while imitating the physiological features of energy injection by way of the ankle joint and energy dissipation by way of the toe joint.
The present disclosure is concerned with methods of chemically modifying a compound to install a thioether linkage, the method comprising reacting the compound with PapB. Also disclosed are thioether compounds produced by such methods that may be useful in, for example, peptide therapeutic uses. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
The present disclosure is concerned with methods of generating interpeptide and intrapeptide thioether linkages and peptides made by such methods. Also disclosed are modified insulin analogs comprising intra- and/or interpeptide thioether linkages. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Described herein are medical film materials that incorporate one or more neuro-regenerative drugs into a polymer film. The polymer film includes a copolymer of lactide and caprolactone. The neuro-regenerative drug includes the macrolactam immunosuppressant FK506. The film is configured such that when placed under physiological conditions, the neuro-regenerative drug is released in an extended, substantially linear fashion for a period of at least 30 days.
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
A dynamic compression implant may be insertable into a bone, and may have a distal member with distal bone-engaging threads, a proximal member that slidably engages the distal member, and a tension member with a proximal end coupled to the proximal member, and a distal end coupled to the distal member such that, in response to motion of the distal member distally away from the proximal member, the tension member elongates and urges the distal member to move proximally toward the proximal member. The bone screw may further have an interpositional member, formed separately from the proximal member and the distal member, that cooperates with the proximal member and the distal member to form a torque transmission feature that transmits torque between the proximal member and the distal member. The dynamic compression implant may be a bone screw, intramedullary implant, or other implant that applies compression across two bone portions.
Examples provide a system for designing a microfluidic device. The system includes an electronic processor configured to receive a set of design inputs defining hardware and operational requirements of a microfluidic device to be designed. Based on the set of design inputs, the electronic processor generates a microfluidic device design by generating an abstracted design of the microfluidic device that includes a machine-readable list of connections and a sequence of liquid processing steps to be performed by the microfluidic device, and, based on the abstracted design, generating a layout of the microfluidic device to determine placement and routing of microfluidic device components and connections between components. The electronic processor performs a simulation of the microfluidic device design, wherein results of the simulation indicate an output chemical concentration, an output flow rate, an output pressure, and/or an output temperature in the microfluidic device design.
G06T 19/00 - Manipulating 3D models or images for computer graphics
G05B 13/00 - Adaptive control systems, i.e. systems automatically adjusting themselves to have a performance which is optimum according to some preassigned criterion
The present disclosure relates to systems and methods for variant detection in Next-Generation Sequencing (NGS) data. The systems and methods detect small variants in NGS data. The systems and methods use a variation detection model to predict two haplotypes present in the sample.
A magnetic cogging parallel-elastic actuator (100) can include a motor (102) having an output shaft (104). The actuator (100) can further include a cogging-torque element (106). The cogging-torque element (106) can include a stator that is stationary relative to the motor (102) and a rotor that is rotatable relative to the stator and comprises an output shaft (104). A plurality of stator magnet elements can be disposed radially about the stator and a plurality of rotor magnet elements can be radially positioned about the rotor. The output shaft (108) of the rotor of the cogging-torque element (106) can be connected in parallel with the output shaft (104) of the motor (102) such that an output torque of the actuator (100) is a sum of a torque of the cogging-torque element (106) and a torque of the motor (102).
Disclosed are prosthetic systems comprising a powered knee upper leg prosthesis and a volitional controller configured to provide control of the prosthesis to the user. The prosthetic system may be configured to enable a user to climb a set of stairs. The prosthetic system may be activated by the activation of an EMG signal source, such as the biceps femoris muscle of the upper leg. The volitional controller of the prosthetic system may be further configured to receive a ground state signal and/or an IMU signal to determine a target knee torque for operating the powered knee of the prosthesis.
A method of producing a neodymium metal can include mixing a dissolution agent comprising magnesium with a neodymium-containing feedstock. The dissolution agent and the neodymium-containing feedstock can be heated to an elevated temperature above a melting temperature of the dissolution agent to form a neodymium-magnesium alloy. The neodymium-magnesium alloy can be exposed to hydrogen gas to convert neodymium in the alloy to a neodymium hydride. The neodymium hydride can be separated from the magnesium in the alloy. The neodymium can be optionally dehydrogenated to yield a purified neodymium product.
A method of modifying a microstructure of a titanium material can include providing a solid titanium material in an inert atmosphere, where the solid titanium material has an initial microstructure with an initial grain size and which is optionally anisotropic. The method can also include introducing hydrogen through a thermal process into the solid titanium material, resulting in a titanium alloy article having a refined microstructure that has a final grain size that is smaller than the initial grain size, or reduced anisotropy, or a combination thereof.
C22F 1/18 - High-melting or refractory metals or alloys based thereon
C22F 1/02 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working in inert or controlled atmosphere or vacuum
20.
COMPOSITIONS AND METHODS FOR TREATING PHOSPHOMANNOMUTASE 2 (PMM2) DEFICIENCY
Disclosed are vectors comprising a nucleic acid sequence capable of encoding Phosphomannomutase 2 (PMM2). Disclosed are vectors comprising a nucleic acid sequence of SEQ ID NO;2. Disclosed are rAAV vectors comprising at least one polynucleotide sequence encoding PMM2. Disclosed are compositions comprising a vector comprising a nucleic acid sequence capable of encoding PMM2. Disclosed are methods of increasing PMM2 expression and/or activity in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a composition comprising a vector comprising a nucleic acid sequence capable of encoding PMM2. Disclosed are methods of glycosylation in cells of a subject in need thereof comprising administering to the subject a therapeutically effective amount of a composition comprising a vector comprising a nucleic acid sequence capable of encoding PMM2. Disclosed are methods of treating a subject having a PMM2 deficiency comprising administering a therapeutically effective amount of a composition comprising a vector comprising a nucleic acid sequence capable of encoding PMM2 to the subject, wherein the composition increases PMM2 expression and/or activity in a cell of the subject.
Disclosed are embodiments of a volitional controller and prosthetic leg system comprising a volitional controller and a powered prosthetic leg. The volitional controller may be configured to control a powered knee joint and a powered ankle joint to enable a user to walk at different speeds and inclines. The orientation of the components of the powered prosthetic leg may be monitored continuously to enable the system to adapt to changes in the duration of the user's gait. The volitional controller may be configured to determine a target knee torque and a target ankle torque that may be based on the global shank orientation, a prosthetic knee velocity, and a prosthetic ankle velocity.
Disclosed are prosthetic systems comprising a powered knee prosthesis and a volitional controller configured to provide control of the prosthesis to the user. The prosthetic system may be configured to enable a user to walk on smooth and/or uneven terrain and to ascend and/or descend stairs. The volitional controller may be configured in a contact state when the prosthesis is in contact with a ground surface and a no contact state when the prosthesis is lifted from the ground surface. When in the contact state, the controller may output a knee torque signal for controlling the powered knee of the prosthesis. The knee torque signal may be based on a target knee torque determined by the knee orientation and the torque measured at the ankle of a prosthetic foot. When in the no contact state, the controller may output a knee torque signal based on a desired knee position.
An optical filter may reduce the frequency and/or severity of photophobic responses or for modulating circadian cycles by controlling light exposure to cells in the human eye in certain wavelengths, such as 480 nm and 590 nm, and a visual spectral response of the human eye. The optical filter may disrupt the isomerization of melanopsin in the human eye reducing the availability of the active isoform, whereas the attenuation of light weighted across the action potential spectrum of the active isoform attenuates the phototransduction cascade leading to photophobic responses. Embodiments of an optical filter are described. In one embodiment an optical filter may be configured to transmit less than a first amount of light in certain wavelengths, and to transmit more than a second amount of light weighted across the visual spectral response. Methods of use and methods of manufacturing optical filters are also described.
A61M 21/02 - Other devices or methods to cause a change in the state of consciousnessDevices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis for inducing sleep or relaxation, e.g. by direct nerve stimulation, hypnosis, analgesia
A61M 21/00 - Other devices or methods to cause a change in the state of consciousnessDevices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
Described herein is a cable-actuated head-neck exoskeleton configured to effectively support and provide mobility to the head-neck. The exoskeleton comprises a head brace, a cable mount, a control unit, and a set of cables. Each cable extends from the control unit, through a defined position in the cable mount, and to a defined position in the head brace. The control unit includes a set of actuators. Each actuator of the set of actuators is connected to one of the cables and independently operates to adjust the length of the corresponding cable. Tension in the cables can therefore be independently adjusted to provide controlled tensile forces to the head and thereby generate moments about the cervical joints of the user.
A method ( 100) of producing a neodymium metal can include mixing (1 10) a dissolution agent comprising magnesium with a neodymium-containing feedstock. The dissolution agent and the neodymium-containing feedstock can be heated (120) to an elevated temperature above a melting temperature of the dissolution agent to form a neodymium-magnesium alloy. The neodymium-magnesium alloy can be exposed (130) to hydrogen gas to convert neodymium in the alloy to a. neodymium hydride. The neodymium hydride can be separated (140) from the magnesium in the alloy. The neodymium can be optionally dehydrogenated (150) to yield a purified neodymium product.
B22F 9/04 - Making metallic powder or suspensions thereofApparatus or devices specially adapted therefor using physical processes starting from solid material, e.g. by crushing, grinding or milling
H01F 1/04 - Magnets or magnetic bodies characterised by the magnetic materials thereforSelection of materials for their magnetic properties of inorganic materials characterised by their coercivity of hard-magnetic materials metals or alloys
H01F 1/01 - Magnets or magnetic bodies characterised by the magnetic materials thereforSelection of materials for their magnetic properties of inorganic materials
26.
DEVICES INCLUDING FERROELECTRIC NEMATIC MATERIAL AND METHODS OF FORMING AND USING SAME
The Regents of the University of Colorado, a body corporate (USA)
University of Utah Research Foundation (USA)
Inventor
Clark, Noel A.
Chen, Xi
Glaser, Matthew A.
Maclennan, Joseph E.
Dong, Degnpan
Bedrov, Dimitry
Abstract
Devices including nematic liquid crystal-forming molecules are disclosed. The molecules include one or more dipoles and exist in a ferroelectric nematic state. Exemplary devices can further include an electrode for applying an electric field in, for example, and in-plane direction.
G02F 1/141 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour based on liquid crystals, e.g. single liquid crystal display cells characterised by the electro-optical or magneto-optical effect, e.g. field-induced phase transition, orientation effect, guest-host interaction or dynamic scattering based on orientation effects in which the liquid crystal remains transparent using ferroelectric liquid crystals
G02F 1/00 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics
G02F 1/01 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour
G02F 1/135 - Liquid crystal cells structurally associated with a photoconducting or a ferro-electric layer, the properties of which can be optically or electrically varied
G16C 10/00 - Computational theoretical chemistry, i.e. ICT specially adapted for theoretical aspects of quantum chemistry, molecular mechanics, molecular dynamics or the like
G16C 20/20 - Identification of molecular entities, parts thereof or of chemical compositions
G21K 1/00 - Arrangements for handling particles or ionising radiation, e.g. focusing or moderating
Disclosed are polypeptides comprising two heterologous polypeptide domains, wherein the first polypeptide domain comprises a Cas protein and wherein the second polypeptide domain comprises a zinc finger protein 865 (ZNF865) or fragment thereof. Disclosed are polynucleotides capable of encoding a polypeptide comprising two heterologous polypeptide domains, wherein the first polypeptide domain comprises a Cas protein and wherein the second polypeptide domain comprises ZNF865 or fragment thereof. Disclosed are vectors comprising one or more of the polynucleotides. Disclosed are methods of using the disclosed polypeptides, polynucleotides and vectors.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
Disclosed herein are polyamide substrates that may be reliably used in additive manufacturing to produce a wide variety of 3D printed articles, protective films or membranes. The polyamide substrate can be formed via thiol-ene click chemistry reactions between diallyl amide or other alkene monomers, reacted with thiol monomers, that can be activated by photoirradiation at relatively low temperatures (e.g., about 80° C.). As a result, the polyamide substrates disclosed herein may be cured using a simple, energy efficient curing process that allows for additive manufacturing where the produced 3d printed article exhibits increased toughness rather than being brittle as are most 3d printed articles.
A trauma gurney includes a base connected to a frame by a vertical adjustment mechanism. The base is configured that it can be maneuvered over a receiving table. The frame holds a detachable platform suitable for the positioning of a patient thereon. Actuation of the adjustment mechanism allows the frame to be lowered and the patient platform to be detached. The patient platform is configured to be non-interfering with various procedures such as MRI procedures so the patient platform can remain with the patient after the patient has been transferred without adverse effects to the procedures. The patient platform can also be reattached to the frame after it has been removed. The trauma gurney beneficially allows a patient to be transferred from the gurney to another surface, such as for imaging, without requiring a conventional lateral transfer. Similarly, the trauma gurney allows a patient to be transferred back to the gurney.
The invention is directed to compounds that are active as antibacterial agents. The invention compounds are active against gram-positive and gram-negative bacteria and can be used to treat infections caused by gram-positive and gram-negative bacteria. Also disclosed are processes and intermediates for making the compounds.
C07D 239/47 - One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
A bone implant system may include a plurality of bone anchors, a superior rod attachable to a superior portion of a bone via the bone anchors, and an inferior rod attachable to an inferior portion of the bone via the bone anchors. The superior rod may have a superior end, and the inferior rod may have an inferior end. The superior rod may telescopically engage the inferior rod such that a cavity is present within at least one of the superior rod and the inferior rod and such that a length of the combined superior and inferior rods, measured between the superior end and the inferior end, is adjustable. The cavity may contain a micropump and a chamber. The micropump may be configured to expel fluid into the chamber to urge the length to increase.
In one aspect, the invention relates to cyclopeptides and methods of using the disclosed cyclopeptides to treat bacterial infections due to, for example, Gram-negative pathogens. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
A parasitic capacitance mitigation circuit for a relaxation oscillator. The parasitic capacitance mitigation circuit includes a first switch coupled across a parasitic capacitance of a resistive sensing element and a second switch coupled between the parasitic capacitance and a reference voltage node. The parasitic capacitance mitigation circuit includes a pulse generator configured to: monitor a voltage across the parasitic capacitance; detect a voltage transient across the parasitic capacitance; and generate a pulse control signal in response to detecting the voltage transient. In response to the pulse control signal, the first switch opens and the second switch closes to discharge the parasitic capacitance through the second switch.
A diffusiophoresis-enhanced particle deposition system can include a deposition surface and a droplet ejector connectable to a supply of particle-containing ink, where the droplet ejector is positioned to eject droplets of the particle-containing ink onto the deposition surface. An atmosphere control chamber can surround the deposition surface. A supply of a solute gas that is soluble in the particle-containing ink can be connected to the atmosphere control chamber to provide a controlled atmospheric concentration of the solute gas to droplets on the deposition surface.
B29C 64/112 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using individual droplets, e.g. from jetting heads
A bone screw may be insertable into a bone. The bone screw may have a distal member with bone-engaging threads, a proximal member configured to slidably engage the distal member, and a tension member with a proximal end coupled to the proximal member, and a distal end coupled to the distal member such that, in response to motion of the distal member away from the proximal member, the tension member elongates and urges the distal member to move toward the proximal member.
Disclosed are methods of treating obesity or an obesity-related condition comprising administering an effective amount of soluble (pro)renin receptor (sPRR) to a subject that is obese or having an obesity-related condition. In some instances, obesity-related conditions can be, but are not limited to, steatosis, hyperglycemia, insulin resistance, chronic renal disease. Disclosed are methods of reducing body weight comprising administering an effective amount of sPRR to a subject in need thereof. Disclosed are methods of treating fatty liver in a subject comprising administering an effective amount of sPRR to a subject in need thereof. Disclosed are methods of treating a fluid and electrolyte disorder comprising administering an effective amount of sPRR to a subject diagnosed with a fluid and electrolyte disorder.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
37.
SYSTEMS AND METHODS FOR FACILITATING RAPID GENOME SEQUENCE ANALYSIS
A method for facilitating rapid genome sequence analysis includes accessing an output stream of an alignment process that includes aligned reads of a biological sequence that are aligned to a reference genome. The method also includes distributing the aligned reads to a plurality of computing nodes based on genomic position. Each of the plurality of computing nodes is assigned to a separate data bin of a plurality of data bins associated with genomic position. The method also includes, for at least one aligned read determined to overlap separate data bins of the plurality of data bins, duplicating the at least one aligned read and distributing the at least one aligned read to separate computing nodes of the plurality of computing nodes that are assigned to the separate data bins.
A microscope imaging system including a microscope having a stage with a well plate having a plurality of therapy treatment samples, an array of light emitting diodes (LEDs) to illuminate the plurality of therapy treatment samples, and a camera to capture images of the plurality of therapy treatment samples over a period of time using the array of LEDs. The microscope imaging system including an electronic controller configured to receive a plurality of images of the plurality of therapy treatment samples over the period of time from the camera, determine a cell mass for each therapy treatment sample based on each image, track the cell mass over the period of time for each therapy treatment sample, determine a plurality of response parameters for each therapy treatment sample based on the tracked cell mass, and determine a treatment response for each therapy treatment sample based on the plurality of response parameters.
Disclosed herein are a polypeptide biosensor and compositions comprising the polypeptide biosensor that detects acetyl coenzyme A (acetyl-CoA). The polypeptide comprises an acetyl-CoA binding protein and a fluorescent protein. Further described herein are methods of using the biosensor to detect acetyl-CoA and expression vectors comprising the biosensor.
Lithium ion batteries and liquid electrolytes for lithium ion batteries are described. An example lithium ion battery can include a cathode, an anode, and a liquid electrolyte in contact with the cathode and the anode. The anode can allow reversible intercalation of lithium ions into the anode. The liquid electrolyte can include a single-oxygen linear ether solvent and a lithium salt at least partially dissolved in the solvent. The lithium salt can include a sulfur-fluorine bond.
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
UNIVERSITY OF UTAH RESEARCH FOUNDATION (USA)
Inventor
Won, Youngwook
Bull, David A.
Lee, Daniel Yongwon
Abstract
Surface-engineered immune cells, such as natural killer cells, grafted with targeting moiety-drug complexes. The present invention combines chemotherapy and immunotherapy by engineering the immune cells to target specific tumor cells through antigen recognition and deliver potent chemotherapeutic agents, thereby destroying the tumor cells. The surface-engineered immune cells may be prepared using a one-step method. The present invention also provides kits for preparing the surface-engineered immune cells.
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
Non-aqueous redox flow batteries (NARFB) including a cation (e.g., trimethylammonium ("TMA")) functionalized polyethylene or other polymeric membrane for mitigating electrolyte crossover. Such a battery can exhibit greater than 99%, or even 99.99% average capacity retention per cycle, with at least 50%, or even at least 85% total capacity retention through 1000 charge/discharge cycles. The trimethylammonium (TMA) or other cation functionalized membrane can be formed from copolymerized cycloalkene polymerizable components, e.g., where the copolymerized cycloalkene polymerizable components comprise a trimethylammonium or other quaternary ammonium substituted cycloalkene polymerizable component and a neutral or unsubstituted cycloalkene polymerizable component in a molar ratio of from 1:1 to 1:20, or 1:1 to 1:10, or 1:2 to 1:6.
43.
CLEAVABLE POLYMER-DRUG CONJUGATES FOR ALZHEIMER'S DISEASE
Described herein are cleavable and non-cleavable polymer-drug conjugates that can cross the blood-brain barrier. An example polymer-drug conjugate includes paclitaxel and a transcytosis peptide that can transport the polymer-drug conjugate across the blood-brain barrier of a subject.. Also described herein are multi-domain conjugates including the polymer-drug conjugate that further include a second cleavable peptide linker. Methods for modulating neurodegenerative conditions with the polymer-drug conjugates and multi-domain conjugates thereof are also described herein.
A61K 47/58 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 31/787 - Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
C07K 7/04 - Linear peptides containing only normal peptide links
A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
Disclosed are polypeptides comprising two heterologous polypeptide domains, wherein the first polypeptide domain comprises a Cas protein and wherein the second polypeptide domain comprises a zinc finger protein 865 (ZNF865) or fragment thereof. Disclosed are polynucleotides capable of encoding a polypeptide comprising two heterologous polypeptide domains, wherein the first polypeptide domain comprises a Cas protein and wherein the second polypeptide domain comprises ZNF865 or fragment thereof. Disclosed are vectors comprising one or more of the polynucleotides. Disclosed are methods of using the disclosed polypeptides, polynucleotides and vectors.
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
C12N 15/66 - General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligationUse of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
Disclosed herein is a first conjugate comprising a first targeting moiety that is adapted to specifically bind to a first antigen on the surface of a target effector cell and a first morpholino oligonucleotide; and a plurality of additional conjugates comprising a targeting moiety that is adapted to bind to a second antigen that is on the surface of a target B-cell and a morpholino oligonucleotide that is at least 90% complementary to the first morpholino oligonucleotide. Also described herein are kits comprising the conjugates and methods for using the conjugates and kits.
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A tether assembly may be attached to a bone to correct a rotational deformity. The bone may have a growth plate that separates a first section of the bone from a second section of the bone. The tether assembly may have a tether member with a first end, a second end, and a central portion extending between the first end and the second end. The first end may have a closed outer wall that defines and fully bounds a first aperture. The second end may have an open outer wall that defines and partially bounds a second aperture. The open outer wall may define a slot in communication with the second aperture. The first and second ends may be securable to the first and second sections of the bone via coupling members inserted through the first and second apertures and anchored in the first and second sections, respectively.
Method and apparatus for detecting and differentiating neurotransmitters using ultraviolet plasmonic-engineered native fluorescence. In one example, the method includes determining a photobleaching rate constant of a neurotransmitter-containing analyte loaded onto a plasmonic-engineered biosensor and subjected to illumination by ultraviolet light. The method further includes submitting a query containing the determined rate constant to a database including calibration data representing a plurality of different neurotransmitters and a plurality of different biosensors. In at least some examples, the queried database returns a response indicating one or more of a predicted identity of the neurotransmitter together with a corresponding confidence score, an estimated amount of the neurotransmitter in the analyte, and an estimated percentage of the neurotransmitter relative to another neurotransmitter in the analyte.
G01N 21/33 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using ultraviolet light
A trephine may be used to form a tunnel through bone and/or cartilage. The trephine may have a trephine body with a generally tubular shape centered on a trephine body longitudinal axis, and a trephine body distal rim. The trephine may also have a drive shaft that receives torque and transmits the torque to the trephine body. The trephine body distal rim may lie substantially in a plane that is non-perpendicular to the trephine body longitudinal axis. The trephine may further have a cutting tooth extending distally from the trephine body distal rim. The cutting tooth may have a first distal tip and a second distal tip displaced circumferentially from the first distal tip. The trephine may be advanced while rotating to form the tunnel through bone and a first, adjacent cartilage surface of a joint, without breaching a second cartilage surface on the opposite side of the joint.
A segmented image-relay fiber can include concatenating image-relay fiber segments. Each segment can include, or consist of, an optical fiber and an imaging lens. Each segment can accurately reproduce (e.g., with little to no losses or distortion of the image) a light intensity distribution in its input plane at its output plane, while reducing the distortion of the image that occurs in many typical fiber optic image transfers. This approach can be used for a variety of applications, such as micro-endoscopy and communication transmissions that can benefit from spatially preserved information. The recorded images can also be analyzed or processed using various computational methods, including machine learning (e.g., a trained algorithm), to enhance performance.
A bone screw may be insertable into a bone. The bone screw may have a distal member with bone-engaging threads, a proximal member configured to slidably engage the distal member, and a tension member with a proximal end coupled to the proximal member, and a distal end coupled to the distal member such that, in response to motion of the distal member away from the proximal member, the tension member elongates and urges the distal member to move toward the proximal member.
e.ge.ge.g, from about 3:2 to about 4:1), wherein the peptide has a minumum chain length, such as, for example a chain length of at least 30 amino acid residues. The disclosed peptides beneficially inhibit ice crystal formation, and, therefore, offer utility in a wide range of applications, including, but not limited to biomedical cryopreservation, food technology, agriculture, cosmetics, and building materials. Thus, the disclosed peptides can be formulated into a composition (e.g, a cryoprotectant composition, an agricultural formulation, a cosmetic composition) or a food product, or, alternatively, can be attached or coated onto a surface for use in structural applications. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
A method of refining a microstructure of a titanium material can include providing a solid titanium material at a temperature below about 400° C. The titanium material can be heated under a hydrogen-containing atmosphere to a hydrogen charging temperature that is above a β transus temperature of the titanium material and below a melting temperature of the titanium material, and held at this temperature for a time sufficient to convert the titanium material to a substantially homogeneous β phase. The titanium material can be cooled under the hydrogen-containing atmosphere to a phase transformation temperature below the β transus temperature and above about 400° C., and held for a time to produce α phase regions. The titanium material can also be held under a substantially hydrogen-free atmosphere or vacuum at a dehydrogenation temperature below the β transus temperature and above the δ phase decomposition temperature to remove hydrogen from the titanium material.
C22F 1/18 - High-melting or refractory metals or alloys based thereon
C22F 1/02 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working in inert or controlled atmosphere or vacuum
A bone anchor may include a shaft having a distal end and a distal toggle element rotatably coupled to the distal end such that the distal toggle element may be rotatable between: a stowed orientation in which the distal toggle element may be insertable into a bone through an aperture formed in a cortex of the bone; and a deployed orientation in which the distal toggle element may be positioned to abut an interior surface of the cortex around the aperture. The bone anchor may also include a flange having a shoulder that may be moveable distally toward the distal toggle element to abut an exterior surface of the cortex.
Disclosed herein is a degradable polyimide substrate that may be reliably used as an electronic substrate in flexible electronics. The degradable polyimide substrate is formed via thiol-ene click chemistry reactions between diallyl imide or other alkene monomers and thiol monomers, that can be activated by photoirradiation at relatively low temperatures (e.g., about 80° C.). As a result, the degradable polyimide substrates disclosed herein may be cured using a simple, energy efficient curing process that allows for streamlined manufacturing of circuits including multilayered circuits. In some instances, epoxy monomers may be added to the monomer resin used to form the polyimide substrate, wherein selective curing may yield polymer substrates with varying degrees of flexibility and rigidity.
H01L 21/48 - Manufacture or treatment of parts, e.g. containers, prior to assembly of the devices, using processes not provided for in a single one of the groups or
H01L 21/56 - Encapsulations, e.g. encapsulating layers, coatings
H01L 23/538 - Arrangements for conducting electric current within the device in operation from one component to another the interconnection structure between a plurality of semiconductor chips being formed on, or in, insulating substrates
Provided herein are compositions, systems, and methods for directed evolution. Further provided herein are compositions, systems, and methods comprising use of synthetic promotor libraries for directed evolution.
C12N 15/66 - General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligationUse of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
56.
UNIQUE MOLECULAR INDEX SEQUENCING FOR GENETIC MUTATIONS
Provided herein are compositions, systems, and methods for directed evolution. Further provided herein are systems and methods comprising use of UMIs with directed evolution.
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C12N 15/66 - General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligationUse of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
A point-of-care diagnostic device configured to measure characteristics of a biological sample. The point-of-care device includes an electronic component package and a complementary metal-oxide-semiconductor (CMOS) biosensor formed on the electronic component package. The CMOS biosensor includes a fluidic system, an electrode array in fluid communication with the fluidic system, and an impedance detection circuit in electrical communication with the electrode detection circuit. The fluidic system is formed on the electronic component package and is configured to transport fluid. The electrode array in fluid communication with the fluidic system and includes a plurality of electrode pairs. The electrode array having a surface coating with an antibody. The impedance detection circuit is in electrical communication with the electrode array and is configured to detect an electrical impedance change caused by a binding of the biological sample to the antibody on each of the electrode pairs.
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
G01N 27/02 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance
G01N 27/12 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance of a solid body in dependence upon absorption of a fluidInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance of a solid body in dependence upon reaction with a fluid
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
A bone anchor may include a shaft having a distal end and a distal toggle element rotatably coupled to the distal end such that the distal toggle element may be rotatable between: a stowed orientation in which the distal toggle element may be insertable into a bone through an aperture formed in a cortex of the bone; and a deployed orientation in which the distal toggle element may be positioned to abut an interior surface of the cortex around the aperture. The bone anchor may also include a flange having a shoulder that may be moveable distally toward the distal toggle element to abut an exterior surface of the cortex.
A semi-powered foot and ankle prosthesis (100) has a foot member (128) coupled to the ankle frame (112) and movable with respect to the ankle frame (112). A linear actuator (144) is coupled to and between the ankle frame (112) and the foot member (128) to move the foot member (128) with respect to the ankle frame (112). The linear actuator (144) has a drive motor (150). A locking mechanism (104) selectively engages the drive motor (150) to selectively lock movement of the drive motor (150) to resist a force on the foot member (128) from backdriving the linear actuator (144).
An inerter-based metamaterial for low-frequency vibration attenuation includes a structural matrix material and an inerter array. The inerter array can be embedded within the structural matrix material. The inerter array can include a first inerter cell oriented along a first attenuation axis and a second inerter cell oriented along a second attenuation axis different from the first attenuation axis. The first inerter cell can include a first inerter. The second inerter cell can include a second inerter. The first inerter and the second inerter can be microinerters. The first inerter cell and the second inerter cell can be separated from each other by at least a portion of the matrix material. The first inerter cell and the second inerter cell can each include a first end and a second end and can each be connected to the matrix material at both the first end and the second end.
E02D 31/08 - Protective arrangements for foundations or foundation structuresGround foundation measures for protecting the soil or the subsoil water, e.g. preventing or counteracting oil pollution against transmission of vibrations or movements in the foundation soil
62.
METHOD FOR DETECTING ANALYTES WITH METAL-ORGANIC FRAMEWORKS
C07F 7/00 - Compounds containing elements of Groups 4 or 14 of the Periodic Table
B01J 20/22 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising organic material
Methods of minimizing dysregulation of Staufen1-associated RNA metabolism can include introducing an amount of a Staufen1-regulating agent to a target cell sufficient to minimize the dysregulation. Therapeutic compositions for treating a neurodegenerative condition associated with Staufen1-induced dysregulation of RNA metabolism can include a therapeutically effective amount of a Staufen1-regulating agent and a pharmaceutically acceptable carrier.
Described herein are systems and methods for electrochemical absorption/desorption for continuous and selective lithium extraction from aqueous lithium feedstocks. The disclosed systems and methods comprise symmetric electrodes having lithium selective material which absorbs and desorbs lithium ions based on an electric field voltage bias. By continuously cycling the voltage bias between positive and negative electric potentials, the absorption and desorption of lithium ions can be selectively controlled to allow efficient lithium extraction.
Provided are recombinant adeno-associated virus (r.AAV) vectors comprising a transgene to express galactose-1-phosphate uridylyl transferase (GALT); virions comprising said vectors (r.AAV virions); methods of their production; methods of their use, including methods for treating galactosemia, GALT-deficiency, symptoms therefrom: and kits. These recombinant adeno-associated virus (rAAV) vectors comprise a method of treating galactosemia in a subject in need.
The disclosure provides a human bone marrow-derived mesenchymal stem cell (hBMSC) sheet comprising one or more layers of human hBMSCs, wherein the cell sheet is prepared from a human clonal bone marrow-derived mesenchymal stem cell line generated from a single cell. The disclosure also provides methods for producing human bone marrow-derived mesenchymal stem cell sheets comprising culturing hBMSCs in culture solution on a temperature-responsive polymer which has been coated onto a substrate surface of a cell culture support, wherein the temperature-responsive polymer has a lower critical solution temperature in water of 0-80° C.; adjusting the temperature of the culture solution to below the lower critical solution temperature, whereby the substrate surface is made hydrophilic and adhesion of the cell sheet to the surface is weakened; and detaching the cell sheet from the culture support. The cell sheet may be treated with interferon gamma (IFN-γ) or basic fibroblast growth factor (bFGF).
Disclosed are devices and methods for improving healing of an enthesis. An effective amount of a composition comprising one or more sex steroids and/or sex steroid equivalents is locally administered at the site of a repaired enthesis. The composition causes upregulation of one or more chondrogenic, angiogenic, and/or tendon modulation genes, resulting in improved healing of the enthesis. The improved enthesis healing occurs even where the subject has normal levels of sex hormones.
A61B 17/00 - Surgical instruments, devices or methods
A61B 17/04 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for suturing woundsHolders or packages for needles or suture materials
A61B 17/06 - NeedlesHolders or packages for needles or suture materials
A base station associated with user devices in a wireless network includes a plurality of base stations. The base station includes a processor and a memory including instructions that, when executed by the processor, cause the base station to function as an actor network configured to determine a current transmit power, a critic network configured to evaluate a quality function of previous transmit powers of the base station based on local observations and previous transmit powers of neighboring base stations, and a decentralized training unit configured to train the quality function over the neighboring base stations. The neighboring base stations are a subset of the plurality of base stations, and the current transmit power is determined based on the previous transmit powers of the base station, direct channel gains between the base station and the user devices, and interference measures from the user devices.
A bone screw may be insertable into a bone, and may have a proximal member, a distal member with bone-engaging threads, wherein the distal member is configured to slidably engage the proximal member such that a variable-length cavity is defined within the proximal member and the distal member, and a tension member residing at least partially within the variable-length cavity. The tension member may have a proximal end coupled to the proximal member and a distal end coupled to the distal member such that, in response to motion of the distal member away from the proximal member, the tension member elongates and urges the distal member to move toward the proximal member. The proximal member and the distal member may be interconnected to share bending loads at a bending transmission feature.
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventor
Schiff, Nicholas
Baker, Jonathan
Butson, Christopher
Janson, Andrew
O'Sullivan, Kyle
Henderson, Jaimie
Choi, Eun Young
Rutt, Brian
Radovan, Matthew
Su, Jason
Abstract
Methods and devices for vector-based targeting of the human central thalamus (CT) to guide deep brain stimulation (DBS) are disclosed. In some examples, electrode(s) each with a plurality contacts are provided. A three-dimensional orientation of a dominant axis of a central lateral nucleus dorsal tegmental tract medial component (CL/DTTm) fiber bundle of a human subject is determined. The contacts of the electrode(s) are positioned in the subject's CT fibers in substantial alignment with the three-dimensional orientation. An electrical stimulus is applied to the contacts to selectively activate the CT fibers. The positioning and the applying are carried out to maximize activation of a central lateral nucleus and medial dorsal tegmental tract fiber pathway in the subject and to minimize activation of a centromedian-parafascicularis fiber pathway in the subject. Methods and devices for surgical planning involving for vector-based targeting of the human CT to guide DBS are also disclosed.
Disclosed is a method for predicting a clinical outcome in a metastatic prostate cancer patient based on measurements of multi-omic features of the patient. A weighting model is selected based on the state of the metastatic prostate cancer (a metastatic hormone sensitive prostate cancer (mHSPC) state or a metastatic castrate resistant prostate cancer (mCRPC) state) and on a clinical outcome of interest. The weighting model maps weights to a series of features (including genetic markers and lipid markers) with respect to the clinical outcome of interest. The weights are generated using a machine learning process that utilizes a training dataset that associates the features of multiple historic metastatic prostate cancer patients with recorded clinical outcomes of those patients. A predictive model generates a probability score for the patient indicating the likelihood of occurrence of the clinical outcome of interest.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
72.
SYSTEMS AND METHODS FOR POINT-OF-CARE ASSESSMENT BASED ON PATHOLOGY IMAGE ANALYSIS
Computing systems, computing devices, computer program products, and computer-implemented methods to assess cancerous bodily tissue samples. The computer-implemented methods include identifying, by a computing device comprising at least one processor, an area within an image of a section of cancerous bodily tissue. The area encompasses cancerous tissue having a grade that is greater than or equal to a threshold grade. The method also includes generating, by the computing device, a feature vector within the area comprising multiple values defining respective targeted histopathologic features of neuroendocrine differentiation. The method further comprises determining a score for the section of cancerous bodily tissue by applying a machine-learning model to the feature vector. The score represents an amount of neuroendocrine differentiation present in the area. The method can be applied by a computing device at point-of-care in order to provide a pathologist or another type of human expert with an assessment of a patient afflicted by cancer.
G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
G06V 10/77 - Processing image or video features in feature spacesArrangements for image or video recognition or understanding using pattern recognition or machine learning using data integration or data reduction, e.g. principal component analysis [PCA] or independent component analysis [ICA] or self-organising maps [SOM]Blind source separation
73.
HIGH-EFFICIENCY ELECTROLYSIS OF IRON ORE FOR IRON PRODUCTION
A method of producing iron metal by electrolysis of iron ore can include introducing iron ore into an anode chamber. The anode chamber can include a first electrolyte and an anode. The anode can oxidize water to form O2 gas and H+ ions in the anode chamber. The iron ore can be dissolved to form Fe3+ and/or Fe2+ ions in the anode chamber. The Fe3+ and/or Fe2+ ions can be transferred from the anode chamber to a cathode chamber through a cation exchange membrane that separates the anode chamber from the cathode chamber. The cathode chamber can include a second electrolyte and a cathode. The Fe3+ and/or Fe2+ ions can be reduced to form iron metal at the cathode.
Disclosed is a method for obtaining digital subtraction angiography (DSA) images using a dynamic frame rate. The method dynamically adjusts frame rates in response to motion artifacts during DSA image acquisition. In situations where there is a high degree of motion, the frame rate can be optimized to increase image quality. On the other hand, in situations where there is a low degree of motion, the frame rate can be lowered to limit the radiation exposure to the patient and provider without overly sacrificing image quality.
A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment
A61B 6/50 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body partsApparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific clinical applications
G06T 5/50 - Image enhancement or restoration using two or more images, e.g. averaging or subtraction
75.
Variable Transmission For Assistive Prosthesis Device
The present disclosure describes transmission systems for use in artificial joints of assistive devices, such as assistive prostheses, orthoses, and powered exoskeletons. A variable transmission is configured to automatically or manually adapt the torque profile to the demand of different locomotion tasks, such as a relatively high torque and low speed profile for a task such as standing up or ascending stairs, or a relatively low torque and high speed profile for a task such as walking.
A61F 2/76 - Means for assembling, fitting, or testing prostheses, e.g. for measuring or balancing
A61F 5/01 - Orthopaedic devices, e.g. long-term immobilising or pressure directing devices for treating broken or deformed bones such as splints, casts or braces
A61H 1/02 - Stretching or bending apparatus for exercising
Disclosed are methods of reducing infarct size in a subject comprising increasing SMYD1 in the subject. Disclosed are methods of reducing myocyte death in a subject comprising increasing SMYD1 in the subject. Disclosed are method of enhancing mitochondrial respiration in a cell comprising increasing SMYD1 in the cell. Disclosed are methods of increasing ATP production in a cell comprising increasing SMYD1 in the cell. Disclosed are methods of protecting a heart from ischemic injury comprising increasing SMYD1 in the heart. Disclosed are vectors comprising a nucleic acid construct, wherein the nucleic acid construct comprises a nucleic acid sequence encoding SMYD1.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Gene therapy methods, vectors and cargo described herein can reduce or prevent C3b amplification and/or MAC formation within the neural retina, retinal pigmented epithelium (RPE), choroid, choriocapillaris (CC), Bruch's membrane and other ocular cells and tissues to re-establish appropriate control of the complement system. Gene therapy methods disclosed will benefit patients with complement related diseases such as AMD. Some gene therapy methods use a viral or nonviral vector comprising a cargo encoding two, three, or more than three activities selected from: a) one or more of a complement proteins selected from CFHT, oCFHT, CFH, and CFI; b) one of more binding proteins that specifically binds CFB, CFD, CFP, CFHR-1, CFHR-2, CFHR-3, CFHR-4, CFHR-5, C3, C4A, C4B, C5, C6, C7, C8A, C8B, C8G, or C9; c) HTRA1 protein or a transcriptional activator protein that increases expression of HTRA1; d) a binding protein that specifically binds ApoE2 or VEGFA; e) an inhibitory RNA that targets CFB, CFD, CFP, FHR-1, CFHR-2, CFHR-3, CFHR-4, CFHR-5, C3, C4A, C4B, C5, C6, C7, C8A, C8B, C8G, or C9; and f) an inhibitory RNA that targets ApoE2 or VEGFA. Also disclosed are optimized forms of truncated Complement Factor H (oCFHT) useful for treatment of patients in gene therapy (delivered alone or in combination with other activities).
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER (Canada)
THE UNIVERSITY OF UTAH (USA)
Inventor
Ibrahim, Ashraf S.
Round, June L.
Ost, Kyla
Abstract
The invention provides a vaccine against inflammatory bowel disease (IBD), such as Crohn's disease, ulcerative colitis, and the like. The vaccine comprises a polypeptide comprising a Candida adhesin antigen, typically an isolated agglutinin-like sequence (Als) protein antigen, formulated with one or more pharmaceutically acceptable carriers or excipients.
Disclosed is a lightweight powered ankle exoskeleton with integrated series-elastic actuation capable of providing high torque and power densities while maintaining a compact and lightweight profile. The exoskeleton includes: a frame configured to be worn adjacent a lower leg of a user; a power transmission assembly integrated with the frame and configured to deliver torque to a crank member to rotate the crank member about an ankle joint; and a foot/shoe interface coupled to the crank member and configured to interface with a foot or shoe of the user and to transmit torque generated at the ankle joint to the foot or shoe of the user.
Disclosed are compositions comprising a peptide and a detectable marker, wherein the peptide comprises a KFERQ motif, wherein the KFERQ motif comprises the amino acid sequence KFERQ (SEQ ID NO: 1). Disclosed are methods of detecting CMA activity in a sample comprising contacting a sample with any of the disclosed compositions, wherein in the presence of CMA activity the KFERQ is cleaved from the detectable marker by a lysosome in the sample; and detecting the presence or absence of cleaved detectable marker.
UNIVERSITY OF MARYLAND BALTIMORE, OFFICE OF TECHNOLOGY TRANSFER (USA)
Inventor
Luetkens, Tim C.
Vander Mause, Erica
Atanackovic, Djordje
Abstract
Disclosed are chimeric antigen receptor (CAR) polypeptides comprising a CD229 antigen binding domain, a transmembrane domain, and an intracellular signaling domain, wherein the CD229 binding domain is a variant CD229 antigen binding domain. Disclosed are chimeric antigen receptor (CAR) polypeptides comprising a CD229 antigen binding domain, a transmembrane domain, and an intracellular signaling domain, wherein the CD229 antigen binding domain comprises the sequence of SEQ ID NO:134, SEQ ID NO:53, or SEQ ID NO:84. Disclosed are methods of using the CAR polypeptides or antibodies comprising the same CD229 antigen binding domain as the CAR polypeptides.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
n3333m31133 is an alkoxyphenyl end group. A fluorescent sensor for detecting marijuana (100) can include the fluorescent sensor compound formed as a. film (110) and a. fluorescence detector (150) oriented to detect a fluorescence response from the fluorescent sensor compound.
C07D 285/14 - ThiadiazolesHydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
C07D 417/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
A system for enabling conversion of speech pantomimes of a user into synthesized speech includes a headset connected to an artificial intelligence network hosted on a computing device. The headset can include an array of distance measurement devices distributed adjacent facial regions of the user associated with speech. The system can further include a microphone and a speaker. Sensor data captured by the distance measuring devices and audio data captured by the microphone are used to train the artificial intelligence network to correlate speech pantomimes of the user with phonemes. The system can output synthesized speech generated from the phonemes through the speaker.
The disclosure relates to methods and compositions comprising atropine and a polymer in a gel formulation for decreasing saliva production and treating sialorrhea.
An exoskeleton device that includes an artificial joint and a frame member extending from the artificial joint. The frame member is configured for extension over a limb of a user. The exoskeleton device also includes a self-aligning mechanism connected to the frame member. The self-aligning mechanism includes three passive degrees of freedom (pDOF) provided in a prismatic-revolute-revolute (PRR) configuration. The self-aligning mechanism also includes a limb attachment member configured for mechanically coupling to a portion of the limb of the user.
Disclosed is an electrochemical biosensor using silver nanoparticles (AgNPs) and screen printed carbon electrodes (SPCEs) that may be used to detect Shiga toxin. The AgNPs are modified with antibodies with specificity to a desired antigen (e.g., Shiga toxin-1). The reference electrode of the SPCEs may be modified with bleach, such that the reference electrode does not significantly contribute to a background signal while measuring the concentration of AgNPs. Related methods can isolate modified AgNP bound antigen molecules, dissolve the modified AgNPs in solution, and detect a concentration of AgNPs using an electrochemical assay that employs the modified SPCE. This detected concentration of AgNPs can subsequently be used to determine the concentration of the target antigen, wherein the concentration of the AgNPs directly correlates to the concentration of the target antigen.
A system for external rotational deformity correction of an intact bone may include: a first frame member and a second frame member rotatably coupled therewith, a first bone fixation member coupled to the first frame member and to a distal segment of the intact bone, a second bone fixation member coupled to the second frame member and to a proximal segment of the intact bone at a first angle, an automated control mechanism coupled to the first and second frame members, and a power source for the automated control mechanism. The automated control mechanism may: receive power from the power source, rotate the first frame member to a desired relative rotational position, and position the first bone fixation member at a desired second angle to exert torsional force on the intact bone and externally reduce rotational deformity of the intact bone.
The present disclosure provides compositions of matter comprising a polymer or peptide bound to an oxidized amino acid or an analog thereof. The present disclosure also provides packaging materials, consumer products, and cosmetic products comprising the compositions of matter disclosed herein.
A PV module cooling assembly can comprise vortex generators and flow deflectors to improve surface convective cooling for a PV module. The vortex generators can comprise one or more winglets attached along an upstream edge portion of the PV module, locally modifying airflow at a front PV module surface by inducing turbulence from the oncoming flow and increasing local convective heat transfer. The flow deflectors can capture and re-direct high-velocity flow to otherwise blocked regions known to recirculate heated air. The PV module cooling assembly is capable of improving surface cooling more than 50% compared to PV modules without flow alteration.
H01L 31/052 - Cooling means directly associated or integrated with the PV cell, e.g. integrated Peltier elements for active cooling or heat sinks directly associated with the PV cells
F24S 10/50 - Solar heat collectors using working fluids the working fluids being conveyed between plates
H01L 31/042 - PV modules or arrays of single PV cells
Disclosed are methods for treating hematologic and solid cancers in a subject, the method comprising administering locally or systemically a therapeutically effective amount of a HRVA2.s and/or HRVA45.s alone or in combination with FDA approved or experimental immunomodulatory agents such that some cells of the cancer undergo viral oncolysis, wherein the host immune system is engaged culminating in host immune activation and tumor regression in the human or animal host. Disclosed are methods for treating viral induced lesions of the skin, including HPV driven papillomas in a subject, the method comprising administering a therapeutically effective amount of HRVA2.s and/or HRVA45.s alone or in combination with immunomodulatory agents such that some cells of the papilloma cells undergo selective viral lysis, wherein the host immune system is engaged culminating in host immune activation and papilloma in the subject.
Described herein are methods for administering a hydrophobic pharmaceutical agent to subjects undergoing extracorporeal membrane oxygenation (ECMO) device therapy while diminishing adsorption of the hydrophobic pharmaceutical agent to the ECMO device. In one embodiment, the method comprises administering the hydrophobic pharmaceutical agent encapsulated in an amphipathic encapsulating agent. In one aspect, the hydrophobic pharmaceutical agent is propofol and the amphipathic encapsulating agent is polyethylene-polypropylene glycol (Poloxamer 407) or a PEGylated liposome. In another aspect, PEGylated propofol is synthesized and used to prevent adsorption to the ECMO device.
Disclosed are polypeptides comprising a diphtheria toxin and a PD1 targeting moiety. Disclosed are polypeptides comprising, from N- to C-terminus, a truncated diphtheria toxin, and two anti-PD-1 scFvs. Disclosed are nucleic acid constructs comprising a nucleic acid sequence encoding any one of the disclosed polypeptides. Disclosed are nucleic acid constructs comprising a nucleic acid sequence encoding a diphtheria toxin linked to a nucleic acid sequence encoding a PD1 targeting moiety. Disclosed are methods of treating a subject in need thereof comprising administering to the subject a composition comprising one or more of the disclosed polypeptides, vectors, or pharmaceutical compositions.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 14/34 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Corynebacterium (G)
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
98.
COMPOSITIONS AND METHODS FOR TREATING PGM1 DEFICIENCY
Disclosed herein, are compositions and methods useful in expressing a functional PGM1 protein in a subject by administration of a recombinant adeno-associated virus vector containing a transgene encoding PGM1. Also disclosed herein are methods for treating a PGM1 gene deficiency in a subject in need thereof.
Disclosed herein are droplets comprising gene editing systems and barcodes. The disclosure further relates to methods for large-scale identification of genes in vivo using barcodes and methods for large-scale identification of gene function in a plurality of subjects using a plurality of droplets.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
Disclosed are a system and method for predicting blood pressure from electrical impedance measurements at the skin. The system includes a wearable device that is configured to be worn against the skin (or attached directly to the skin) above a target vessel, such as a target artery. The wearable device includes an array of electrodes that enable measurement of electrical impedance at the skin. The system receives a series of electrical impedance measurements from the wearable device, and based on the series of electrical impedance measurements, calculates a blood pressure prediction using a predictive model that is informed by the incompressible Navier-Stokes equations for a tube with elastic boundary conditions and by the Maxwell-Fricke equations relating red blood cell orientation and distribution to blood conductivity.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 40/60 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
